TY - JOUR T1 - New drugs for peripheral joint psoriatic arthritis JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 1 LP - 5 DO - 10.1136/dtb.2006.4411 VL - 44 IS - 1 A2 - , Y1 - 2006/01/01 UR - http://dtb.bmj.com/content/44/1/1.abstract N2 - Relevant BNF section: 10.1Up to 3% of people have psoriasis, and as many as 42% of these have an associated chronic inflammatory arthritis.1 In up to 20% of such patients, the arthritis progresses to become severe, destructive and deforming.2–5 Traditional drug treatments include NSAIDs and disease-modifying anti-rheumatic drugs (DMARDs) used for rheumatoid arthritis. ▼Leflunomide (Arava - Sanofi-Aventis), ▼etanercept (Enbrel - Wyeth) ▼inifliximab (Remicade - Schering-Plough) and ▼adalimumab (Humira - Abbott) are licensed for the treatment of patients with peripheral joint disease in psoriatic arthritis. Here we review drug therapy for such patients, concentrating on the newer agents. ER -